<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01766245</url>
  </required_header>
  <id_info>
    <org_study_id>NN9535-4010</org_study_id>
    <secondary_id>2012-002212-20</secondary_id>
    <secondary_id>U1111-1130-3931</secondary_id>
    <nct_id>NCT01766245</nct_id>
  </id_info>
  <brief_title>A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes</brief_title>
  <official_title>A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of the trial is to investigate the bioequivalence
      (assessment of the expected biological equivalence of two pharmaceutical drug products with
      identical active ingredient) between subcutaneous injections of semaglutide produced by two
      manufacturing processes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma semaglutide concentration curve</measure>
    <time_frame>0-4 weeks after a single dose s.c. semaglutide administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax, the maximum plasma semaglutide concentration</measure>
    <time_frame>20-40 hours after a single dose s.c. semaglutide administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The area under the plasma semaglutide concentration curve</measure>
    <time_frame>From time 0 to infinity after a single dose s.c. semaglutide administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax, time to Cmax of semaglutide</measure>
    <time_frame>20-40 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tÂ½, terminal elimination half-life of semaglutide</measure>
    <time_frame>140-200 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>From first dosing to follow-up (5-7 weeks after the second dosing)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycaemic episodes</measure>
    <time_frame>From first dosing to follow-up (5-7 weeks after the second dosing)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Diabetes</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Formulation A followed by Formulation B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation B followed by Formulation A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>semaglutide</intervention_name>
    <description>For subcutaneous (s.c., under the skin), single dose administration at two separate dosing visits.</description>
    <arm_group_label>Formulation A followed by Formulation B</arm_group_label>
    <arm_group_label>Formulation B followed by Formulation A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects

          -  Body mass index (BMI) of 18.5-30 kg/m^2 (both incl.)

        Exclusion Criteria:

          -  History of or presence of cancer, diabetes, pancreatitis or any clinically relevant
             cardiovascular diseases or other major disorders

          -  Use of prescription or non-prescription medicinal products (except routine vitamins,
             acetylsalicylic acid and paracetamol) within 3 weeks (or within 5 half-lives of the
             medicinal product, whichever is longest) prior to the first dosing of semaglutide

          -  Smoking, drug or alcohol abuse

          -  Female of childbearing potential who is pregnant, breast-feeding or intend to become
             pregnant or not using adequate contraceptive methods for the duration of the trial and
             for 3 months following the last dose of semaglutide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2012</study_first_submitted>
  <study_first_submitted_qc>January 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2013</study_first_posted>
  <last_update_submitted>June 24, 2014</last_update_submitted>
  <last_update_submitted_qc>June 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mm</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

